38949-70-1

Usage

Uses

Used in Pharmaceutical Industry:
[2-(3,4-dichlorophenoxy)ethyl]amine hydrochloride is used as an intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs and medications.
Used in Agrochemical Industry:
In the agrochemical industry, [2-(3,4-dichlorophenoxy)ethyl]amine hydrochloride is used as an intermediate in the production of pesticides, highlighting its importance in creating effective solutions for agricultural needs.
Used in Organic Synthesis:
[2-(3,4-dichlorophenoxy)ethyl]amine hydrochloride is also utilized as a reagent for organic synthesis, allowing for the creation of a wide range of chemical products and contributing to the advancement of chemical research.
Used in Biomedical Research and Drug Development:
[2-(3,4-dichlorophenoxy)ethyl]amine hydrochloride holds potential applications in biomedical research and drug development due to its unique chemical structure and properties, which can be harnessed to explore new therapeutic approaches and drug candidates.

Upstream product

• 29947-85-1 N-[2-(3,4-dichloro-phenoxy)-ethyl]-phthalimide 
• 333799-81-8 tert-butyl 2-(3,4-dichlorophenoxy)ethylcarbamate 
• 95-77-2 3,4-dichlorophenol 
• 38949-69-8 (3,4-Dichloro-phenoxy)-acetonitrile 

Downstream Products

• 1019641-21-4 1-(3,5-bis-trifluoromethyl-phenyl)-3-[2-(3,4-dichloro-phenoxy)-ethyl]-thiourea 
• 1192366-83-8 N-(2-(3,4-dichlorophenoxy)ethyl)-2-(4-(methylsulfonamido)phenoxy)acetamide 
• 1266246-47-2 1-(2-(3,4-dichlorophenoxy)ethyl)-6-phenyl-1,6-dihydro-1,3,5-triazine-2,4-diamine hydrochloride 

Relevant academic research and scientific papers

Synthesis, structural activity-relationships, and biological evaluation of novel amide-based allosteric binding site antagonists in NR1A/NR2B N-methyl-d-aspartate receptors

The synthesis and structure-activity relationship analysis of a novel class of amide-based biaryl NR2B-selective NMDA receptor antagonists are presented. Some of the studied compounds are potent, selective, non-competitive, and voltage-independent antagonists of NR2B-containing NMDA receptors. Like the founding member of this class of antagonists (ifenprodil), several interesting compounds of the series bind to the amino terminal domain of the NR2B subunit to inhibit function. Analogue potency is modulated by linker length, flexibility, and hydrogen bonding opportunities. However, unlike previously described classes of NR2B-selective NMDA antagonists that exhibit off-target activity at a variety of monoamine receptors, the compounds described herein show much diminished effects against the hERG channel and α1-adrenergic receptors. Selections of the compounds discussed have acceptable half-lives in vivo and are predicted to permeate the blood-brain barrier. These data together suggest that masking charged atoms on the linker region of NR2B-selective antagonists can decrease undesirable side effects while still maintaining on-target potency.

ANTI-INFECTIVE THIOUREA COMPOUNDS

The present application discloses thiourea compounds for use in the treatment of infections. The thiourea compounds have formula (I) wherein X1 and X2 each designate one or more substituents; and Z is-(CHR)-, -(CHR)2-, -O-(CHR)2-, -NH-(CHR)2-, or -S-(CHR)2-; including salts thereof.

SUBSTITUTED 2H-[1,2,4]TRIAZOLO[4,3-A]PYRAZINES AS GSK-3 INHIBITORS

The invention relates to compounds of formula (I) prodrugs thereof, and the pahrmaceutically acceptabel salts of the compounds and prodrugs, wherein Ra, Rb, R1 and R2 are as defined herein; pharmaceutical compositions thereof; and uses thereof.